Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Free Access

Drugs, Biogenic Amine Targets and the Developing Brain

Frederick A.L.a · Stanwood G.D.b, c

Author affiliations

aNeuroscience Graduate Program, bDepartment of Pharmacology, and cVanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, Tenn., USA

Corresponding Author

Gregg D. Stanwood, PhD

Vanderbilt Kennedy Center

23rd Ave South, 476 RRB

Nashville, TN 37232-6600 (USA)

Tel. +1 615 936 3861, Fax +1 615 936 2202, E-Mail gregg.stanwood@vanderbilt.edu

Related Articles for ""

Dev Neurosci 2009;31:7–22

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Defects in the development of the brain have a profound impact on mature brain functions and underlying psychopathology. Classical neurotransmitters and neuromodulators, such as dopamine, serotonin, norepinephrine, acetylcholine, glutamate and GABA, have pleiotropic effects during brain development. In other words, these molecules produce multiple diverse effects to serve as regulators of distinct cellular functions at different times in neurodevelopment. These systems are impacted upon by abuse of a variety of illicit drugs, neurotherapeutics and environmental contaminants. In this review, we describe the impact of drugs and chemicals on brain formation and function in animal models and in human populations, highlighting sensitive periods and effects that may not emerge until later in life.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Review

Received: May 19, 2008
Accepted: August 09, 2008
Published online: April 17, 2009
Issue release date: April 2009

Number of Print Pages: 16
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: http://www.karger.com/DNE

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.